1. Recent Articles

    1. Desogestrel DOWN-REGULATES PHOX2B And Its Target Genes In Progesterone Responsive Neuroblastoma Cells.

      DESOGESTREL DOWN-REGULATES PHOX2B AND ITS TARGET GENES IN PROGESTERONE RESPONSIVE NEUROBLASTOMA CELLS.

      Exp Cell Res. 2018 Jul 20;:

      Authors: Cardani S, Di Lascio S, Belperio D, Di Biase E, Ceccherini I, Benfante R, Fornasari D

      Abstract The paired-like homeobox 2B gene (PHOX2B) encodes a key transcription factor that plays a role in the development of the autonomic nervous system and the neural structures involved in controlling breathing.

      Read Full Article
      Mentions: PHOX2B
    2. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.

      GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.

      Apoptosis. 2018 Jul 19;:

      Authors: Durbas M, Pabisz P, Wawak K, Wiśniewska A, Boratyn E, Nowak I, Horwacik I, Woźnicka O, Rokita H

      Read Full Article
      Mentions: Antibody
    3. Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.

      Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.

      J Pediatr Surg. 2018 Jul 06;:

      Authors: Fahy AS, Roberts A, Nasr A, Irwin MS, Gerstle JT

      Abstract PURPOSE: The impact of the extent of surgical resection including nephrectomy for high-risk neuroblastoma patients is controversial.

      Read Full Article
      Mentions: Surgery
    4. Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Proc Natl Acad Sci U S A. 2018 Jul 18;:

      Authors: Kerosuo L, Neppala P, Hsin J, Mohlin S, Vieceli FM, Török Z, Laine A, Westermarck J, Bronner ME

      Read Full Article
      Mentions: MYCN
    5. Parental perception of child vulnerability in childhood cancer survivors.

      Parental perception of child vulnerability in childhood cancer survivors.

      Pediatr Blood Cancer. 2018 Jul 19;:e27364

      Authors: Staba Hogan MJ, Ross WL, Balsamo L, Mitchell HR, Kadan-Lottick NS

      Abstract BACKGROUND: Parents' perception of their children's vulnerability to illness following cancer treatment is largely unknown, but is important to understand given known challenges of transitioning survivors to postcancer care.

      Read Full Article
      Mentions: Treatment
    6. Exercise linked to reduced mortality in survivors of childhood cancer

      Exercise linked to reduced mortality in survivors of childhood cancer

      1. In this retrospective cohort analysis, adult survivors of childhood cancer demonstrated reduced mortality with increasing levels of vigorous exercise in a week. 2. Increasing the degree of vigorous exercise was also linked to a reduction in mortality compared to maintaining activity levels. Evidence Rating Level: 3 (Average)       Study Rundown: Adult survivors of childhood cancer []

      Read Full Article
    7. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      J Control Release. 2018 Jul 03;285:162-171

      Authors: Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B

      Abstract High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment.

      Read Full Article
    8. An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      Oncotarget. 2018 Jun 26;9(49):29082-29096

      Authors: Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M, Mairs R

      Abstract Targeted radiotherapy of metastatic neuroblastoma using the somatostatin receptor (SSTR)-targeted octreotide analogue DOTATATE radiolabelled with lutetium-177 (177Lu-DOTATATE) is a promising strategy.

      Read Full Article
    9. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Biol Direct. 2018 Jul 16;13(1):14

      Authors: Suo C, Deng W, Vu TN, Li M, Shi L, Pawitan Y

      Abstract BACKGROUND: Neuroblastoma is the most common pediatric malignancy with heterogeneous clinical behaviors, ranging from spontaneous regression to aggressive progression.

      Read Full Article
      Mentions: MYCN
    10. Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Oncol Lett. 2018 Aug;16(2):2439-2443

      Authors: Zhang X, Li C, Xu C, Hao X, Yu X, Li Q

      Abstract Correlation between computed tomography (CT) signs, lymphatic metastasis and pathological features of neuroblastoma (NB) in children was investigated.

      Read Full Article
      Mentions: Metastasis
    11. Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

      Risk stratification is crucial to treatment decision‐making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting outcome in patients aged ≥18 months with metastatic neuroblastoma and to develop a simple risk score for prognostication.

      Read Full Article
      Mentions: Treatment SIOPEN MYCN
    12. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Pediatr Blood Cancer. 2018 Jul 14;:e27354

      Authors: Druy AE, Shorikov EV, Tsaur GA, Popov AM, Zaychikov AN, Tuponogov SN, Saveliev LI, Tytgat GAM, Fechina LG

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    13. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR

      Expression of PHOX2B , TH , ELAVL4 , and B4GALNT1 (GD2‐synthase) was analyzed by quantitative polymerase chain reaction in neuroblastoma cell lines, control BM samples, and in BM samples from patients. The threshold level of expression for each gene was established through receiver operator characteristic analysis and used to determine the diagnostic test performance. The prognostic significance of BM involvement was assessed by survival rates calculations.

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    14. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    There are no recent topics in the news.

  3. Recent Quotes

    1. We continue to expand our broad array of proprietary T cell programming technologies designed to tackle specific aspects of tumour biology and we are pleased to highlight the article published in Molecular Therapy about our novel small-molecule-activated permanent off switch.
      By Christian Itin
    2. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    3. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    4. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    5. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    6. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    7. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    8. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    9. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    10. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju